OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/ROS1
Lung Cancer — Non-Small Cell (NSCLC)ROS1 Clinical Trials
ROS1 fusions occur in approximately 1–2% of NSCLC and are actionable targets for ROS1-directed TKIs. FDA-approved options for locally advanced or metastatic ROS1-positive NSCLC include crizotinib, entrectinib, repotrectinib, and taletrectinib. Repotrectinib and taletrectinib are approved for both TKI-naïve and previously ROS1-TKI-treated patients. Active trials investigate later-line strategies, CNS-active agents, combinations, and resistance mechanisms.
Top recruiting ROS1 Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count.
See all trials matched to your profile →Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio Inc.
Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC
Dr Arvindran A/L Alaga
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Nuvation Bio Inc.
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
Intergroupe Francophone de Cancerologie Thoracique
Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC
Shouyao Holdings (Beijing) Co. LTD
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Sinocelltech Ltd.
More ROS1 Lung Cancer — Non-Small Cell (NSCLC) trials
See all in search →13 international trials (no US sites)
FDA-approved therapies for ROS1 Lung Cancer — Non-Small Cell (NSCLC)
Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.